Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY crawled time : 00:00 save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Global Dilated Cardiomyopathy (DCM) Market Report 2024, with Company Profiles of the Top 10 Major Market Players
Published: 2024-03-07 (Crawled : 00:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.21%
H: 0.0%
C: -1.71%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.08%
H: 0.86%
C: 0.7%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.03%
H: 0.62%
C: 0.5%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.02%
H: 1.37%
C: 0.34%
company report global market
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -1.53%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 1.71%
H: 1.28%
C: 0.94%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.28%
H: 0.18%
C: 0.0%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.09%
H: 0.39%
C: -0.36%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.15%
H: 2.4%
C: 0.56%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -1.4%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.4%
H: 0.19%
C: -0.33%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
report cancer blood growth market
Global Erectile Dysfunction Drugs Market Research Report 2024: Novel Drug Launches Propel Growth, Growing Geriatric Population Drives Demand - Forecast to 2034
Published: 2024-01-16 (Crawled : 00:00) - prnewswire.com
MGRX | $0.286 -4.64% -4.86% 78K
|
|
| O: 3.28%
H: 4.38%
C: -0.19%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.03%
H: 0.05%
C: 0.05%
PTPI | $0.6849 -1.86% -1.9% 150K
|
|
| O: 0.38%
H: 0.0%
C: -7.58%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.34%
H: 0.0%
C: 0.0%
drug propel report research global growing market
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.65%
H: 0.69%
C: -0.73%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -2.19%
obesity first chinese key trial
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published: 2024-01-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.41%
C: 0.41%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.43%
H: 2.12%
C: 2.03%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.64%
H: 4.97%
C: 4.9%
ibi362 obesity first chinese study
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Published: 2023-12-18 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.25%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.03%
H: 0.06%
C: -2.67%
ibi362 obesity publication communications chinese results
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
Published: 2023-10-30 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
ibi362 obesity metabolic favorable treatment study benefits
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published: 2023-10-26 (Crawled : 00:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
bge-105 agonist treatment collaboration trial tirzepatide
Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
total study tirzepatide
Testosterone Replacement Therapy Market to Reach $2.22 Billion by 2027, Driven by Rising Testosterone Deficiency Cases
Published: 2023-07-25 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.34%
H: 0.69%
C: -0.05%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
reach therapy market
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.65%
H: 0.49%
C: 0.07%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.35%
H: 2.21%
C: 1.9%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.33%
H: 2.55%
C: 1.4%
treatment designation china therapy study
Biosimilars Market Research Report 2023 - Global Forecast to 2028 - Patent Expiries of Blockbuster Biologics and Research into New Indications Presents Opportunities
Published: 2023-07-05 (Crawled : 00:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.17%
H: 0.63%
C: 0.22%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -2.54%
H: 10.78%
C: 10.04%
AMPH | $39.98 3.44% 3.33% 410K
|
Health Technology
|
| O: -0.52%
H: 1.38%
C: -0.38%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: -0.86%
patent report research global market
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
Published: 2023-06-26 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.06%
H: 0.91%
C: 0.72%
tyvyt tumors collaboration trial china therapy
Generic Central Nervous System Drugs Global Market Report 2023: Major Players Include Otsuka Pharmaceutical, Astra Zeneca, Shire, Novartis and Teva Pharmaceutical Industries
Published: 2023-06-19 (Crawled : 00:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 0.06%
C: -0.61%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.0%
H: 0.32%
C: -0.52%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.41%
H: 2.02%
C: 1.37%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.11%
H: 1.35%
C: 0.53%
ALKS | $23.86 0.42% 0.42% 2.4M
|
Health Technology
|
| O: 0.47%
H: 0.46%
C: 0.28%
report global system novartis teva market
Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
Published: 2023-06-12 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.02%
H: 0.19%
C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.2%
H: 1.57%
C: 1.54%
ibi322 treatment meeting
Historic Actos RICO Class Action Against Big Pharma Could be Worth Billions
Published: 2023-06-05 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.8%
H: 0.23%
C: -1.06%
pharma
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.8%
H: 0.23%
C: -1.06%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
ibi351 asco cancer meeting
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.